|
CO-ADMINISTRATION WITH DRUGS HAVING NARROW THERAPEUTIC INDEX SHOULD BE APPROACHED WITH CAUTION AS IT MAY CAUSE EARLY & SEVERE SIDE EFFECTS
|
MAY CAUSE ORTHOSTATIC HYPOTENSION
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
INCREASED SEDATIVE EFFECT
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|